Nutrichem 颖泰生物
2 significant filings since 31 May 2026: 2 on regulatory inquiry. The latest, on 8 Jul 2026: 北京颖泰嘉和生物科技股份有限公司关于对北京证券交易所2025年年报问询函回复的公告.
自 31 May 2026 起有 2 份重大公告：regulatory inquiry 2 份。最新一份（8 Jul 2026）：北京颖泰嘉和生物科技股份有限公司关于对北京证券交易所2025年年报问询函回复的公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 5 Mar 2024 | 开源证券 | 诸海滨 | Buy 买入 | ▼ | Outperform 增持 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 开源证券 | 诸海滨 | Outperform 增持 | 29 Apr 2026 | 3 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。